We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
9
1 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
1982
Active, not recruiting
1
11.1%
Completed
5
55.6%
Recruiting
2
22.2%
Withdrawn
No approval data available
- Bexorg has been awarded a research grant from The Michael J. Fox Foundation to identify translational biomarkers for TRPML1-targeted Parkinson's disease therapies using its postmortem whole-human brain platform. - TRPML1 has emerged as a compelling therapeutic target for Parkinson's disease, but the lack of translational biomarkers to confirm target engagement in clinical trials has been a significant obstacle. - The company will leverage its proprietary BrainEx platform to identify biomarkers in brains donated by people who lived with Parkinson's disease, potentially accelerating multiple TRPML1-targeted therapeutic programs. - Bexorg's approach addresses the critical translational gap in CNS drug development, where clinical trial failure rates exceed 95% due to inadequate preclinical models.
